Biopharmaceutical Stocks: The Next Phase Of The Rally Appears To Be Underway

Aug. 16, 2024 12:00 PM ETXBI8 Comments
Leonard Yaffe
2.73K Followers
(4min)

Summary

  • Stock valuations in the pharmaceutical industry are becoming more attractive for potential mergers due to declining IPO prices.
  • Aging population and prevalence of chronic diseases are driving favorable prospects for the drug industry.
  • Advances in oncology, hematology, and genetics medicines are revolutionizing treatment for various diseases, with promising late-stage clinical studies.

Scientist pipetting samples into eppendorf tubes

Morsa Images

Eight months ago, with the XBI at $85.50, I wrote an article suggesting that biopharmaceutical stocks should begin to rally. The subsequent action has been standard, with upthrusts followed by corrections. My thinking has been that a sufficient number

This article was written by

2.73K Followers
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Related Stocks

SymbolLast Price% Chg
XBI--
SPDR® S&P Biotech ETF

Related Analysis